Dendritic Cell Vaccine
The active ingredients in this vaccine are dendritic cells designed to activate the patient’s immune system to restore their body’s ability to control the activities of cancer cells.
In cases of oncological illness, the immune system is not capable of controlling the growth of tumour cells. To restore the system’s functions, it is necessary to modulate its activities using immunotherapy.
DCV offers therapeutic solutions for breast cancer, brain cancer, stomach cancer, uterine cancer, colon cancer, melanoma, kidney cancer, liver cancer, sarcoma, and others. There is also strong scientific evidence that suggests that DCV can limit the aggressiveness of cancer.
Blood monocytes are first isolated from the patient and then converted into dendritic cells in the laboratory. These cells are used to make DCV by saturating them with the patient’s cancer antigens and allowing them to mature. DCV does not affect cancer directly; the therapeutic effect is instead caused by “nurturing” the immune system so that rather than tolerating the cancer cells, it recognizes them and takes action to control their activities.
Individual types of cancer immunotherapy can be applied to the treatment of melanoma, kidney cancer, prostate cancer and gliomas of the central nervous system (brain and spinal cord). They can also be used to treat other malignancies, according to the doctor’s permission.
Immunotherapy treatments for cancer are performed at a medical institution, and our laboratory will produce and issue a certified preparation for use at such an establishment in line with a doctor’s prescription. The doctor’s treatment plan for the patient can consist of combiningthe dendritic cell vaccine with other standard methods of cancer therapy.
Immunotherapy treatments are changing the landscape of how we think about fighting advanced disease. Groundbreaking clinical cancer treatments are being highlighted among the medical community, of those, Dendritic Cell Vaccines (DCV) is one we offer here at Amber Life Cancer Clinic. Let us explain how and why we offer DCV in our clinical practice.
What is a Dendritic Cell?
A dendritic cell is an accessory immune cell, which has antigen-presenting properties. The singular purpose of an antigen-presenter cell or dendritic cell is to process antigens and present them to the specific immune cells – T cells. Basically, the dendritic cells send a message to the T cells to begin their job of defending the immune system.
What is Dendritic Cell Vaccine Therapy?
Dendritic cell vaccine therapy starts with the practice of extracting or isolating a small portion of cancer. A small sample of blood is also removed from the same patient and then filtered down through a unique process to isolate the dendritic cells specifically from our own immune system. In a laboratory environment, the isolated cancer sample and the dendritic cell sample are introduced together. The result is a potent dendritic cell vaccine ready to be administered back into the patient. The immune system is being reshaped which contributes to immunogenic (mediated by the immune system) cancer cell death. DCV is a very simple injection and patients tend to tolerate DCV therapy very well. Most patients report zero adverse effects after the administration of DCV.
- HIV 1 and 2 (p24 Ag)
- Syphilis TPHA
- Syphilis RPR
- Hepatitis B antigen (HBsAg)
- Hepatitis B core antibody (HBcor)
- Hepatitis B antibody (HBs)
- Hepatitis C antibody (HCV)
- General blood test
By being approved and later purchasing DCV treatment patient will receive medicine and our Doctors’ monitoring for up to one year. Depends on a number of produced vaccines.
Dendritic Cell Vaccine Therapy Shows Promise in Treating Cancer
Dendritic Cell Vaccine therapy is a promising method and it is why ALCC utilizes it in the clinical practice. DCV offers therapeutic solutions for many different cancer types at various stages of the disease. These cancers include breast cancer, brain cancer, stomach cancer, uterine cancer, colon cancer, melanoma, kidney cancer, liver cancer, sarcoma, and others. There is also strong scientific evidence that suggests that DCV can limit the aggressiveness of cancer.
Several research studies have highlighted the therapeutic potential of DCV therapy in the following medical journals:
In a clinical study chronicling cases of advanced melanoma and corresponding immunotherapy treatment with DCV, the result was prolonged life. The patients taking part in the study protocol were able to receive a positive prognosis following the DCV due to the result of increased T-cell activity.
Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. The future of DC therapy lies in combining this form of active specific immunotherapy with other therapies to increase the antitumor activity of the immune effector cells.